PEPGEN INC.
PEPGEN Inc (PEPG) is a small-cap biotechnology company with a market capitalisation around $335 million. The business focuses on developing therapeutic candidates and related technologies typical of biopharmaceutical firms, with progress driven by research and development, clinical milestones and potential partnerships. For investors, key considerations include the company’s pipeline stage, cash runway and any upcoming trial readouts or regulatory events that can materially affect the share price. Small-cap biotech stocks can be volatile and outcomes are often binary — success or setback in clinical programmes can cause significant moves. Monitor financial reports, funding needs and collaboration agreements. This summary is for general educational purposes only and does not constitute investment advice; speak to a regulated financial adviser to assess suitability. Past performance is not indicative of future results and capital is at risk.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pepgen's stock with a target price of $16, indicating strong potential growth.
Financial Health
Pepgen Inc. shows strong cash flow and book value, indicating good financial stability and performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PEPG
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketThe Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Matter
Trial readouts and regulatory steps can sharply move the stock; outcomes are uncertain and can be binary.
R&D And Cash Needs
Research and development are capital intensive — monitor cash runway and potential dilution from future financing.
Partnerships And Licensing
Collaborations can provide funding and validation, but terms and commercial success vary; assess agreements carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
